Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

On October 4, 2024 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, reported that three abstracts highlighting its pipeline of clinical product candidates and anti-exhaustion technology have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) taking place in Houston, TX, Nov. 6-10, 2024 (Press release, Lyell Immunopharma, OCT 4, 2024, View Source [SID1234647031]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The three presentations highlight anti-exhaustion technology and product candidates being advanced in Lyell’s pipeline of cell therapies for solid tumors and hematologic malignancies, including the first presentation at a scientific conference of translational data from the LYL797 Phase 1 clinical trial demonstrating solid tumor infiltration and cell killing by reprogrammed ROR1 CAR T cells.

Details of the poster presentations are below:

LYL797 ROR1 CAR T-cell Translational Data Demonstrated T-cell Reprogramming Limited Exhaustion, Maintained Stemness, and Resulted in Tumor Infiltration and Cell Killing in Patients with Solid Tumors

Abstract Number: 285
Presentation Date & Time: Friday, Nov. 8, 2024, 12:15-1:45 p.m. and 5:25-6:55 p.m.
Multiomic profiling of LYL119: A Reprogrammed ROR1 CAR T Product Generates T cells with Reduced Exhaustion and Enhanced Memory Characteristics Associated with Increased AP-1 and Reduced NR4A Bindings

Abstract Number: 283
Presentation Date & Time: Friday, Nov. 8, 2024, 12:15-1:45 p.m. and 5:25-6:55 p.m.
Utilizing Stim-R Technology to Reduce Irradiated Feeder Cells in the Tumor Infiltrating Lymphocyte Culture Process

Abstract Number: 440
Presentation Date & Time: Saturday Nov. 9, 2024, 12:00-1:30 p.m. and 7-8:30 p.m.